On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.
On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6]
In 2019, the entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.
In November 2022, Kyowa Kirin announced plans to spin its international established medicines portfolio into a new joint venture with German company Grünenthal. [7]
In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million.[8]
Business segments and productsedit
Pharmaceuticals business
The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.[9]
^"Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio". www.businesswire.com. 2022-11-24. Retrieved 2022-11-29.
^"Kyowa Kirin to acquire Orchard Therapeutics for $478 million". Reuters. 2023-10-05. Retrieved 2023-10-05.
^Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081.
^. Kyowa Hakko Kirin. Archived from the original on March 4, 2016. Retrieved March 14, 2014.
kyowa, kirin, 協和キリン株式会社, kyōwa, kirin, kabushiki, kaisha, japanese, pharmaceutical, biotechnology, company, under, kirin, holdings, among, largest, world, revenue, company, headquartered, chiyoda, tokyo, member, nikkei, stock, index, headquarters, otemachi, ch. Kyowa Kirin Co Ltd 協和キリン株式会社 Kyōwa Kirin Kabushiki Kaisha is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings and is among the 40 largest in the world by revenue The company is headquartered in Chiyoda ku Tokyo and is a member of the Nikkei 225 stock index 4 5 Kyowa Kirin Co Ltd Headquarters in Otemachi Chiyoda TokyoCompany typePublic K K Traded asTYO 4151Nikkei 225 ComponentIndustryPharmaceuticalsBiotechnologyFoundedJuly 1 1949 74 years ago 1949 07 01 HeadquartersOhtemachi Building 1 6 1 Ōtemachi Chiyoda ku Tokyo 100 8185 JapanKey peopleNobuo Hanai CEO and President ProductsBiochemicalsBiosimilarsDiagnosticsPharmaceuticalsRevenue 2 99 billion USD FY 2022 398 4 billion JPY FY 2022 Net income 375 million USD FY 2022 53 6 billion JPY FY 2022 Number of employees7 532 consolidated as of December 31 2017 ParentKirin Holdings Company LimitedSubsidiaries47 33 in Japan and 14 overseas countries WebsiteOfficial websiteFootnotes references 1 2 3 Contents 1 History 2 Business segments and products 3 References 4 External linksHistory editOn July 1 1949 the forerunner of the present company Kyowa Hakko Kogyo Co Ltd is established Following the merger with Kirin Pharma Co Ltd on October 1 2008 the company changed its name to its present On July 11 2014 the KHK subsidiary ProStrakan Group based in Scotland acquired Archimedes Pharma from the Novo Nordisk Foundation for 394 million 6 In 2019 the entity was renamed Kyowa Kirin Co Ltd replacing its prior name of Kyowa Hakko Kirin Co Ltd In November 2022 Kyowa Kirin announced plans to spin its international established medicines portfolio into a new joint venture with German company Grunenthal 7 In October 2023 Kyowa Kirin acquired a Britain based biopharmaceutical company Orchard Therapeutics for 478 million 8 Business segments and products editPharmaceuticals businessThe company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out the company calls this its Potelligent platform The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform 9 Central nervous system medicines Immunology Allergy medicines Nephrology medicines ESPO NESP Aranesp REGPARA Oncology medicines ABSTRAL GRAN Peglasta Neulasta LEUNASE Mitomycin C SANCUSO Diagnostics In vitro diagnostic reagents analyzers and companion diagnostics Bio Chemicals business Biosimilars Monoclonal Antibodies Amino acids nucleic acids and related compounds health care products and other active pharmaceutical ingredients Vitamins minerals peptides and plant growth regulators 10 References edit Kyowa Hakko Kirin Company Overview Kyowa Hakko Kirin Retrieved March 14 2014 Kyowa Hakko Kirin Corporate Profile PDF Kyowa Hakko Kirin Retrieved March 14 2014 Kyowa Hakko Kirin Annual Report 2012 Kyowa Hakko Kirin Retrieved March 14 2014 Components Nikkei Stock Average Nikkei Inc Retrieved January 20 2015 Top 50 Pharma Companies by 2012 Revenue Wildwood Ventures Ltd Archived from the original on February 8 2014 Retrieved March 14 2014 ProStrakan Acquires Archimedes Pharma for 394M Genetic Engineering amp Biotechnology News Mary Ann Liebert Inc July 11 2014 Retrieved January 20 2015 Grunenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio www businesswire com 2022 11 24 Retrieved 2022 11 29 Kyowa Kirin to acquire Orchard Therapeutics for 478 million Reuters 2023 10 05 Retrieved 2023 10 05 Yu X Marshall MJE Cragg MS Crispin M June 2017 Improving Antibody Based Cancer Therapeutics Through Glycan Engineering PDF BioDrugs 31 3 151 166 doi 10 1007 s40259 017 0223 8 PMID 28466278 S2CID 3722081 FY 2013 Consolidated Financial Summary Kyowa Hakko Kirin Archived from the original on March 4 2016 Retrieved March 14 2014 External links edit nbsp Japan portal nbsp Medicine portal nbsp Tokyo portal nbsp Companies portalOfficial website Retrieved from https en wikipedia org w index php title Kyowa Kirin amp oldid 1217551319, wikipedia, wiki, book, books, library,
